Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us

Targeting global unmet need for rapid molecular diagnostic for human TB

PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing Service.
  • January 19, 2023
  • Company, Latest
  • dairy, human TB, TB diagnostic
global unmet need for rapid molecular diagnostic for human TB

TB is a preventable and treatable condition that is second only to Covid as the most fatal infectious disease worldwide. A recent report has highlighted that Actiphage is the only rapid molecular diagnostic currently in development that can detect subclinical human TB from a blood sample, consequently the company has committed to supporting the fight to #EndTB.

Size and urgency of unmet need

Jane Theaker, CEO of PBD Biotech, the developer of Actiphage comments: “The size and urgency of the unmet need for human TB diagnostics has driven our decision to focus in the short term on this goal. The proof of concept clinical trials have gone well, and we are talking to pharma companies about the use of Actiphage for developing therapeutics as well as the application for screening and triage.”

“Research for animal health – Bovine TB and Johne’s Disease – will continue in parallel with academic partners. We are still keen to receive expressions of interest in this research area but will be unable to provide the commercial service in the near term.”

Molecular diagnostic for rapid screening

Actiphage is novel as it uses a bacteriophage, specific to a strain of mycobacteria, to find the bacteria in blood, it replicates quickly breaking open the cell walls to enable identification of the mycobacterial DNA with PCR. This allows swift screening of a population and early diagnosis of those that are at most risk of developing the disease.

Most other tests, such as IGRA, detect the host’s immune response and this occurs later when the disease has progressed.

Additionally, other tests use a sample of sputum which is difficult for children and many adults to produce.

WHO Target Product Performance

WHO and FIND have identified the development of rapid molecular diagnostic as a research priority and created a clearly defined Target Product Performance criteria. This has not happened in animal health. Therefore, PBD Biotech has a clear route to market for its Actiphage test in human health.

Knowledge emerging from the human programme could benefit animal health.

To discuss this further please contact us.

The Treatment Action Group (TAG) Pipeline Report Tuberculosis Diagnostics published in November 2022, highlights Actiphage® as the only blood-based diagnostic in development for subclinical tuberculosis that directly detects mycobacteria and provides an early indication of disease progression.

Share:

Related posts

Loading...
Marie Roskrow

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair

January 17, 2023
Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need, PBD Biotech is announcing that it has appointed Dr Marie Roskrow to chair its board and has expanded its scientific...
Marie Roskrow

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair

January 17, 2023
Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need,...
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic with potential to revolutionise management of TB.
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic...
Rapid Research in Diagnostics Development for TB Network R2D2 TB Network

Promising TB diagnostic Actiphage selected for evaluation by R2D2 TB Network

September 30, 2022
Ease of use at the point of need is vital for the roll out of a diagnostic, so PBD Biotech, developers of Actiphage - a rapid blood test for early-stage tuberculosis - is partnering with the Rapid Research in Diagnostics...
Rapid Research in Diagnostics Development for TB Network R2D2 TB Network

Promising TB diagnostic Actiphage selected for evaluation by R2D2 TB Network

September 30, 2022
Ease of use at the point of need is vital for the roll out of a diagnostic, so PBD Biotech,...
ECCMID

Actiphage TB diagnostic finds live mycobacterium tuberculosis in the blood of people with incipient TB

April 23, 2022
A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live bacteria can be detected in the blood of people with incipient TB infection.
ECCMID

Actiphage TB diagnostic finds live mycobacterium tuberculosis in the blood of people with incipient TB

April 23, 2022
A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live...
1 2 3 Next »

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB

Read More
PBD Biotech

Delighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies

Read More
PBD Biotech

Testing 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease

Read More